Mr.Allen has 30 years of experience in business and finance, including 16 years in executive leadership positions with technology and med-tech businesses. In 1998 Mr. Allen co-founded Regeneration Technologies, Inc. (Nasdaq:RTIX), developing the company's strategic business plan, negotiating the spin-off of the company’s underlying technology from the University of Florida, raising the initial venture capital, and leading its initial public offering in 2000.
Mr. Allen is also the founder of Synogen, a private venture fund investing in early-stage biomedical and medical device companies, and co-founder of Emergent Growth Fund, an angel investment fund. With a background in technology, business and finance, he has had responsibility for finance, business development, IT, HR, IR, technology licensing and M&A, and has negotiated several acquisitions as well as venture capital funding for several successful start-ups. He is also co-founder and director of Sustainable Cambodia, a 501(c)(3) nonprofit organization working to create a sustainable quality of life in Cambodian villages.
David Corddry has been a member of our Board since August 2014. Mr. Corddry is a certified public accountant. Since 2005, Mr. Corddry has been the Chief Financial Officer for United Medical Corporation, comprising a diversified group of healthcare companies, including ownership and management of acute care and specialty hospitals. From 2004 to 2005, Mr. Corddry was a Division Controller for Invivo Corporation, a manufacturer of patient monitors and magnetic resonance imaging equipment. From 1998 to 2004, Mr. Corddry was a Division Controller for IKON Office Solutions, a provider of document management systems and services (which was purchased by Ricoh Company, Ltd. in 2008). Mr. Corddry earned his bachelor’s degree in business at Michigan State University in 1989, his master’s degree of business from the Crummer School of Business at Rollins College in 1997, and his Bachelor of Science of Accounting at Florida Southern College in 2005. Mr. Corddry was chosen to serve on our Board as a result of his financial and accounting experience, as well as his management experience in the healthcare industry.
Dr. Gold has combined academic achievement with business and management expertise in a successful career in medicine, academics and finance. He is currently serving as Dizney Eminent Scholar and Distinguished Professor at the University of Florida College of Medicine's Brain Institute in the Departments of Psychiatry, Neuroscience, Anesthesiology, Community Health & Family Medicine, where he is also Interim Chair and Chief in the Division of Addiction Medicine.
Over his 35 year translational research career, Dr. Gold has done extensive laboratory and clinical research with drugs of abuse, medications, adherence and monitoring. In the field of medical technology, he is a co-inventor of technology for testing of medication Dr. Gold and his Yale colleagues pioneered and automated cocaine testing in blood and urine as well as for other drugs of abuse. adherence and compliance, and therapeutic drug monitoring for medication used to treat epilepsy and other medical conditions. Dr Gold has had considerable experience and success in developing laboratory models for addictions and then developing new treatments. He is one of a very few researchers to have patented important new uses for existing medications without a university as a co-inventor or owner of the patent, and to have then sold the patent to a major multinational pharmaceutical company for manufacture and marketing.
Dr. Gold combines his medical knowledge with many years of experience in business and finance, where he has consulted for companies such as Medtronic, Ciba-Geigy, Merck, Wyeth, Roche, Alkermes, Dupont, Glaxo, Abbott, and Forest Laboratories. He was a major investor and founding member for Aklaim Video, the company responsible for the leading video game Mortal Kombat. He was a co-founder and founding director of Somerset Valley Bank, helping the bank go from concept to its first bank opening, to a chain, to its public listing on NASDAQ and to its sale for nearly $100 million. Dr. Gold has provided consulting services to top-tier financial firms such as Goldman Sachs, Lehman Brothers, Oppenheimer, the Carlyle Group and Smith Barney, as well as currently co-authoring a subscription financial newsletter for Phillips.
As a world-renowned addiction researcher, Dr. Gold has been involved in the development of numerous new approaches which have rapidly progressed from bench-to-bedside. His research has led to changes in the treatment of physician addiction, opiate and cocaine addiction and food addiction. He is the author of twelve professional books and over 900 medical articles, chapters, and abstracts in journals for health professionals. He is frequently the expert interviewed for comment by the Wall Street Journal ,other major business, and national publications concerned with the strengths and limitations of new technology and treatments in obesity, pain, drug addiction and psychiatry.
John Harper is an active private equity investor and on the Executive Committee of SpringBoard Capital Partners II. He was the Entrepreneur in Residence at The Innovation Factory, a medical device incubator until January 1, 2006. Previously, he was President and Chief Executive Officer of ATI Medical, a company specializing in the treatment of cancer. Prior to that he was Executive Chairman of Meretekdiagnostics, inc. a company specializing in diagnostic breath tests using isotope labeled substrates to identify disease in the body. Meretek merged with Diasorin a division of American Standard Companies. Previously Mr. Harper was President and Chief Executive Officer of Índigo Medical, Inc. a medical laser company specializing in the minimally invasive treatment of BPH. Mr. Harper successfully merged Índigo with Ethicon EndoSurgery a division of Johnson & Johnson. Prior to joining Índigo Medical, Mr. Harper was President and Chief Executive Officer of Menlo Care, Inc. a manufacturer of specialty vascular access and urology devices. Mr. Harper completed a merger between Menlo Care and Johnson & Johnson Medical a division of Johnson & Johnson. Previously, Mr. Harper managed his own investment business that resulted in the creation of three companies, one was sold to a private investment group, one to a publicly NASDAQ traded company and one sold to a publicly NYSE traded company. Prior, Mr. Harper spent 11 years with Physio Control a cardiac monitor and defibrillation company in sales management. Mr. Harper received his Bachelor of Arts in Economics from Davidson College in 1971.
Mr. Johnson is an original investor and founding Board member of Xhale, Inc. He is a member of the family that founded Johnson and Johnson (NYSE:JNJ), and remains interested in translational, medical research and innovation. Both a philanthropist and businessman who has distinguished himself in local, regional and national start ups, Mr. Johnson was a founder of the Somerset Valley Bank, a one-location bank started in a remodeled house in the County seat near the Johnson family home in New Jersey. From these humble beginnings, the bank grew to a regional chain, financial service firm, NASDAQ listing, and ultimately purchase by Fulton Financial. Mr. Johnson remained active on the BOD and Committees for over a decade. He is a Florida resident who serves on the Board of Directors of the Benjamin School. Mr. Johnson regularly evaluates new technology and treatments when visiting the University of Florida. He helped fund the UF start up Viewray, a novel radiation oncology company formed after a McKnight Brain Institute scientific discovery and patent. Viewray has since moved from Gainesville to Cleveland and has received major investments from Orbimed, Fidelity and the State of Ohio as it prepares to bring its novel approach to cancer treatment to market this year.
Terence Mullervy has been a member of our Board since August 2014. Mr. Mullervy spent 34 years in international banking and finance. After graduating from the credit training program at the Chase Manhattan Bank in New York, he was sent on a variety of assignments over 14 years with the bank. He was a corporate lending officer, responsible for asset quality, product innovation and marketing in the Bank’s corporate finance units in Mexico City and London. He worked as an expat in those locations for over 10 years. During his time in London, Mr. Mullervy was an account officer and managed a section of the Commodity Division; arranging financing for European based trading houses. Aside from line assignments, Mr. Mullervy also held staff positions at the bank. He was an instructor in the Bank’s credit training program both in New York and Puerto Rico, teaching the curriculum, developing then leading case studies and mentoring the analysts. Towards the end of his career with Chase, Mr. Mullervy was the Chief of Staff to the head of the Bank’s Global Trading and Securities Sector. He was responsible for coordinating market analysis, product development and financial management units and provided daily briefings to the executive on sector wide issues. From there, Mr. Mullervy moved to the trading floor to become a crude oil trader for Chase.
In 1987 Mr. Mullervy was recruited by the privately held Swiss based trading house, Glencore A.G., as the Treasurer of Glencore Ltd. based in Stamford Ct. There he managed the treasury function of Glencore’s Western Hemisphere oil, metals and agri business operation including funding, investment, hedging , counterparty credit risk analysis and portfolio administration . In 1989, Mr. Mullervy was made a partner in Glecnore A. G. In 1998 Mr. Mullervy returned to London, this time as Finance Director for Glencore UK Ltd., where he managed all aspects of the finance, compliance and legal functions for Glencore’s worldwide oil business. While in this role, he raised capital on behalf of Glencore A. G. in over two dozen transactions from investors in the Euro, Asian and US markets. Mr. Mullervy was a Board member of Glencore UK Ltd, Glencore Commodities UK and was a member of the New York Mercantile Exchange. Mr. Mullervy retired as a partner of Glencore A. G. after more than 20 years with the firm. Since then he has been an active as a private investor in a number startup companies focused primarily on health care.
Nauman Toor joined the Xhale, Inc. Board in July of 2014. Since December 2012, Mr. Toor has served as a Partner and the Chief Investment Officer of Luzich Partners LLC, a multi-strategy investment firm, which he cofounded. Since January 2007, Mr. Toor has served as the chief investment officer of BlackRoot Capital, an investment fund focused on small-cap public equities and special situations, which he founded. From 2001 to 2006, Mr. Toor served as Managing Director of Jefferies & Company Inc. (Jefferies), an investment bank. He served as Head of Media Investment Banking at Jefferies from 2002 to 2006, where he began working in 1994. During his tenure, Jefferies became the largest middle market focused investment bank in the country, with an increase in market value from $50 million to over $3 billion. Mr. Toor was promoted as the youngest Managing Director in the firm’s history and has led financing transactions in excess of $10 billion as well as M&A and restructuring arrangements in excess of $3 billion.
Mr. Toor started his career in investment banking with Kidder Peabody & Company, where he worked from 1990 to 1994. He has been Director of AVP Inc. since May 2008. Mr. Toor earned a Bachelor of Arts degree in Economics from Ohio Wesleyan University in 1990 and a Masters in Business Administration from Harvard Business School in 1994.